View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
October 11, 2019updated 12 Jul 2022 12:23pm

Seattle Genetics starts combination therapy trial in breast cancer

Seattle Genetics has commenced dosing in a Phase III clinical trial of its tucatinib drug in combination with Kadcyla (ado-trastuzumab emtansine) in HER2-positive (HER2+) breast cancer patients.

Seattle Genetics has commenced dosing in a Phase III clinical trial of its tucatinib drug in combination with Kadcyla (ado-trastuzumab emtansine) in HER2-positive (HER2+) breast cancer patients.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Tucatinib is an investigational, oral, small-molecule tyrosine kinase inhibitor with high selectivity for HER2 that is overexpressed in various cancer types, including breast cancer.

The drug is said to lack significant EGFR inhibition, which is linked to toxicities such as skin rash and diarrhoea.

Seattle Genetics noted that Tucatinib demonstrated activity as a monotherapy, as well as in combination with chemotherapy and other HER2 targeting drugs such as trastuzumab.

It holds orphan drug designation from the Food and Drug Administration (FDA) for breast cancer patients with brain metastases.

Named HER2CLIMB-02, the multi-centre, randomised, double-blind, placebo-controlled Phase III study will compare the combination therapy to placebo plus Kadcyla in around 460 patients with unresectable locally-advanced or metastatic HER2+ breast cancer.

The trial will enrol patients who previously received a taxane and trastuzumab treatment in any setting.

The primary endpoint of the trial is progression-free survival, while secondary endpoints include overall survival, objective response rate and duration of response.

Data from the Phase III trial is expected to support registration in the US.

Seattle Genetics chief medical officer Roger Dansey said: “We are building a comprehensive strategy for tucatinib in combination with other medicines across a range of HER2-positive cancers.

“We are pleased to advance this tucatinib clinical trial with the vision of improving combination outcomes for patients with HER2-positive metastatic breast cancer who receive T-DM1. This trial has the potential to support tucatinib use in earlier lines of therapy.”

The company is also assessing tucatinib in the ongoing, pivotal HER2CLIMB trial in combination with capecitabine and trastuzumab for the treatment of pretreated, unresectable, locally advanced or metastatic HER2-positive breast cancer.

The drug is also being developed to treat other solid tumours, including colorectal cancer.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena